What is CRISPR Therapeutics's change in deferred revenue?

CRISPR Therapeutics (CRSP) reported change in deferred revenue of -$427K in Q1 2026.

How has CRISPR Therapeutics's change in deferred revenue changed year-over-year?

CRISPR Therapeutics's change in deferred revenue increased by 48.2% year-over-year, from -$824K to -$427K.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

CRISPR Therapeutics CRSP Change in Deferred Revenue

Change in Deferred Revenue at other companies

Arrowhead ResearchARWR

$163.36M—

BridgeBio PharmaBBIO

-$2.38M+7.5%

Regeneron PharmaceuticalsREGN

$99.6M+463%

PTC TherapeuticsPTCT

-$1.52M-121%

Protagonist TherapeuticsPTGX

-$3.27M+40.5%

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's change in deferred revenue?: CRISPR Therapeutics (CRSP) reported change in deferred revenue of -$427K in Q1 2026.
How has CRISPR Therapeutics's change in deferred revenue changed year-over-year?: CRISPR Therapeutics's change in deferred revenue increased by 48.2% year-over-year, from -$824K to -$427K.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.